|
|
|
|
|
|
|
M T Wed Th F |
|
5 August, 2026 |
|
|
|
|
|
|
|
|
|
|
Google DeepMind CEO Demis Hassabis is stepping down to become Alphabet's science chief. But as Andrew Dunn reports, Hassabis will lean into his role at Isomorphic Labs to help reshape drug R&D with AI. |
|
|
|
Kevin Miller |
Deputy Editor, Endpoints News
|
|
|
|
 |
|
Demis Hassabis, outgoing CEO of Google DeepMind (Jose Sarmento Matos/Bloomberg via Getty Images) |
|
|
|
by Andrew Dunn
|
Alphabet is shaking up its AI leadership, with Demis Hassabis stepping down as CEO of Google DeepMind and becoming Alphabet's chief scientist. Longtime Google chief... | |
|
|
|
|
|
|
|
|
by Anna Brown
|
WuXi AppTec, the Chinese contract manufacturer under scrutiny from the Pentagon, isn't slowing down. For the first time, the company appears to have generated more... | |
|
|
|
 |
|
Steven Quay, Atossa Therapeutics CEO |
|
|
|
by Zachary Brennan
|
Steven Quay, the founder and CEO of clinical-stage biotech Atossa Therapeutics, is likely to be the next director of NIH's National Institute of Allergy and Infectious... | |
|
|
|
|
|
|
by Max Gelman
|
So much for that. AstraZeneca and Bristol Myers Squibb are no longer in discussions on a merger and will not strike a deal, Reuters reported... | |
|
|
|
|
|
|
by Elizabeth Cairns
|
“If you don't like setbacks and you don't like failure, don't get into the pharma industry,” Novo Nordisk CEO Maziar Mike Doustdar said on a... | |
|
|
|
|
|
|
by Kyle LaHucik
|
Eli Lilly posted $23 billion in second-quarter revenues, coming in about $3 billion above analysts' estimates. Lilly also once again raised its full-year revenue
guidance... | |
|
|
|
 |
|
Yi Larson, Expedition Therapeutics CEO |
|
|
